Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.

Haas NB, Powles TB, Tomczak P, Park SH, Venugopal B, Symeonides SN, Ferguson T, Chang YH, Lee JL, Sawrycki P, Sarwar N, Gurney H, Gross-Goupil M, Burke JM, Doshi G, Cornell J, Burgents JE, Perini RF, Choueiri TK

Open source

DOI: 10.1016/j.annonc.2026.08.006
Published: 2026 Aug 26
Container: Annals of oncology : official journal of the European Society for Medical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2026.08.006,
  title = {Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.},
  author = {Haas NB and Powles TB and Tomczak P and Park SH and Venugopal B and Symeonides SN and Ferguson T and Chang YH and Lee JL and Sawrycki P and Sarwar N and Gurney H and Gross-Goupil M and Burke JM and Doshi G and Cornell J and Burgents JE and Perini RF and Choueiri TK},
  year = {2026},
  journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
  doi = {10.1016/j.annonc.2026.08.006},
  url = {https://doi.org/10.1016/j.annonc.2026.08.006}
}

RIS

TY  - JOUR
TI  - Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.
AU  - Haas NB
AU  - Powles TB
AU  - Tomczak P
AU  - Park SH
AU  - Venugopal B
AU  - Symeonides SN
AU  - Ferguson T
AU  - Chang YH
AU  - Lee JL
AU  - Sawrycki P
AU  - Sarwar N
AU  - Gurney H
AU  - Gross-Goupil M
AU  - Burke JM
AU  - Doshi G
AU  - Cornell J
AU  - Burgents JE
AU  - Perini RF
AU  - Choueiri TK
PY  - 2026
JO  - Annals of oncology : official journal of the European Society for Medical Oncology
DO  - 10.1016/j.annonc.2026.08.006
UR  - https://doi.org/10.1016/j.annonc.2026.08.006
ER  -

APA

NB, H., TB, P., P, T., SH, P., B, V., SN, S., T, F., YH, C., JL, L., P, S., N, S., H, G., M, G., JM, B., G, D., J, C., JE, B., RF, P., & TK, C. (2026). Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2026.08.006

Source records

pubmed · retrieved 2026-09-26T00:33:18.879Z